论文部分内容阅读
以肝细胞癌单克隆抗体ＨＡｂ１８为载体，用葡聚糖作桥的间接交联方法和氯胺Ｔ法，同时将阿霉素（ＡＤＭ）和１３１Ｉ连接到ＨＡｂ１８上，制备出“双弹头”肝癌免疫导向药物１３１Ｉ－ＨＡｂ１８－ＡＤＭ。其免疫结合率为４３．５％。细胞毒实验结果显示，１３１Ｉ－ＨＡｂ１８－ＡＤＭ对靶肿瘤细胞ＳＭＭＣ－７７２１的杀伤效果较单独应用ＡＤＭ相同浓度的ＨＡｂ１８－ＡＤＭ和比放射性相同的１３１Ｉ－ＨＡｂ１８时，有明显的增强。１３１Ｉ－ＨＡｂ１８－ＡＤＭ具有选择性高效杀伤的作用，它集中了化疗与内放射治疗的优点，互相补充，展示了肿瘤导向治疗的良好前景。
The hepatocellular carcinoma monoclonal antibody HAb18 was used as the carrier, dextran was used as the bridge indirect cross-linking method and chloramine T method, and adriamycin (ADM) and 131I were attached to HAb18 to prepare a “double warhead” liver cancer. Immune-directed drug 131I-HAb18-ADM. Its immune binding rate was 43.5%. The results of cytotoxicity test showed that the killing effect of 131I-HAb18-ADM on target tumor cell SMMC-7721 was significantly enhanced compared with HAb18-ADM with the same concentration of ADM alone and 131I-HAb18 with the same radioactivity. 131I-HAb18-ADM has a selective and highly effective killing effect. It concentrates the advantages of chemotherapy and internal radiation therapy and supplements each other, demonstrating the good prospects of tumor-directed therapy.